Efficacy and immune response analysis of concurrent chemoradiotherapy combined with camrelizumab in advanced non-small cell lung cancer
GAO Guangyi
DONG Chunrong
MA Jun
JIANG Xuan
Abstract：Objective To evaluate the efficacy and safety of concurrent chemoradiotherapy combined with camrelizumab in the treatment of advanced non-small cell lung cancer(NSCLC)and to analyze the immune response status of patients.Methods A total of 90 patients with advanced NSCLC admitted to Huai'an Second People's Hospital from January 2020 to March 2023 were enrolled.All patients received concurrent chemoradiotherapy(prescribed total radiation dose:60 Gy,delivered in 30 fractions at 2 Gy per fraction).In the combination group(n=50),patients received camrelizumab(200 mg,intravenous infusion,once every 3 weeks)in addition to concurrent chemoradiotherapy,while the control group(n=40)received concurrent chemoradiotherapy alone.Short-term efficacy was assessed after 4 cycles of treatment using the Response Evaluation Criteria in Solid Tumors version 1.1,with objective response rate(ORR)and disease control rate(DCR)calculated.Long-term survival outcomes were evaluated through follow-up to obtain progression-free survival(PFS)and overall survival(OS).Safety was assessed by recording treatment-related adverse events according to the Common Terminology Criteria for Adverse Events version 4.03 of the National Cancer Institute.Flow cytometry was used to detect dynamic changes in the proportions of total T lymphocytes(CD3+),helper/inducer T lymphocytes(CD4),and cytotoxic T lymphocytes(CD8+)in peripheral blood,as well as the CD4+/CD8+ratio before and after treatment.Results Among the 90 patients evaluable for efficacy,the ORR and DCR in the combination group were 32.0％and 80.0％,respectively,while those in the control group were 15.0％and 55.0％,respectively.The difference in ORR between the groups did not reach statistical significance(P=0.062),but the DCR in the combination group was significantly higher than that in the control group(P=0.011).Survival analysis showed that the median PFS and OS in the combination group were 9.7 months and 30.6 months,respectively,both significantly longer than those in the control group(6.4 months and 12.7 months,respectively;all P＜0.05).After treatment,the proportions of CD3+and CD4+T lymphocytes,as well as the CD4+/CD8+ratio,significantly increased in the combination group,while the proportion of CD8+T lymphocytes significantly decreased.Moreover,the improvements in all these indicators were significantly greater in the combination group than in the control group(all P＜0.001).Regarding safety,the main adverse reactions were grade 1-2,with an overall incidence of grade 3 adverse reactions of 5.6％.Furthermore,there were no statistically significant differences in the incidence of any adverse reactions between the two groups(all P＞0.05).Conclusion Concurrent chemoradiotherapy combined with camrelizumab significantly improves the disease control rate and survival outcomes in patients with advanced NSCLC,enhances immune function,and demonstrates a favorable safety profile.This regimen exhibits a synergistic effect between chemoradiotherapy and immunotherapy,indicating promising clinical application prospects.
Keywords：Non-small cell lung cancerConcurrent chemoradiotherapyCamrelizumabEfficacyImmune response status
Publication Date：2026-01-28
Online Publishing Date：2026-03-18(First online date of this platform, not the publication date of the document)
Pages：6( 73-78 )